Photocure-North America Cystoscopes Market to Exhibit Steady Gro
Cystoscopes Market Expected To Reach US$ 207.2 Mn By 2026
Growing awareness of cystoscopes and its ease of use, accounts for rise in its demand among ambulatory care services leading to fastest growth rate during the forecast period. As reported by Photocure ASA (February 2018), 1.2 million cystoscopies are performed annually in the U.S. This value is further expected to increase during the forecast period owing to rising prevalence of bladder cancer, bladder stones, and cystitis. The growing prevalence of urologic conditions thus catalyzes the overall market growth in North America.
Video cystoscopes accounted for maximum market share in 2017 and attained fastest growth rate during the forecast period from 2018 to 2026. This trend is followed by the growth of flexible non-video cystoscopes. The use of video cystoscopes increases the efficiency of diagnostic and therapeutic procedures thus augmenting their demand. On the other hand, flexible non-video cystoscopes are comparatively lower priced and their flexible nature ensures patient comfort and less painful procedure. Additionally, newer technologies namely, Blue Light Cystoscopy with Cysview enables enhanced diagnosis of cancerous cells. The Cysview (hexaminolevulinate HCl) gets absorbed by cancerous cells and glows pink under blue light. This development has further catalyzed the video cystoscopes market growth. Additionally, growing prevalence of bladder cancer, high patient awareness coupled with uniform product accessibility, minimally invasive technique and reduced procedural time benefits, contribute to the lucrativeness of video cystoscopes.
Presence of skilled professionals, ease of availability of cystoscopy techniques, suitable reimbursement benefits, and high disposable incomes are the major factors for hospitals, significantly contribute to the overall cystoscopes market growth. Rising healthcare establishments and increasing benefits for health insurance companies primarily account for the fastest growth rate of ambulatory care services during the forecast period from 2018 to 2026. According to an article published on American College of Surgeons (FACS) (2017), a shift of outpatient procedures from hospitals to ambulatory care services would save US$ 25 Bn to Medicare over 10 years.
http://www.credenceresearch.com/report/north-america-cystoscopes-market
Growing awareness of cystoscopes and its ease of use, accounts for rise in its demand among ambulatory care services leading to fastest growth rate during the forecast period. As reported by Photocure ASA (February 2018), 1.2 million cystoscopies are performed annually in the U.S. This value is further expected to increase during the forecast period owing to rising prevalence of bladder cancer, bladder stones, and cystitis. The growing prevalence of urologic conditions thus catalyzes the overall market growth in North America.
Video cystoscopes accounted for maximum market share in 2017 and attained fastest growth rate during the forecast period from 2018 to 2026. This trend is followed by the growth of flexible non-video cystoscopes. The use of video cystoscopes increases the efficiency of diagnostic and therapeutic procedures thus augmenting their demand. On the other hand, flexible non-video cystoscopes are comparatively lower priced and their flexible nature ensures patient comfort and less painful procedure. Additionally, newer technologies namely, Blue Light Cystoscopy with Cysview enables enhanced diagnosis of cancerous cells. The Cysview (hexaminolevulinate HCl) gets absorbed by cancerous cells and glows pink under blue light. This development has further catalyzed the video cystoscopes market growth. Additionally, growing prevalence of bladder cancer, high patient awareness coupled with uniform product accessibility, minimally invasive technique and reduced procedural time benefits, contribute to the lucrativeness of video cystoscopes.
Presence of skilled professionals, ease of availability of cystoscopy techniques, suitable reimbursement benefits, and high disposable incomes are the major factors for hospitals, significantly contribute to the overall cystoscopes market growth. Rising healthcare establishments and increasing benefits for health insurance companies primarily account for the fastest growth rate of ambulatory care services during the forecast period from 2018 to 2026. According to an article published on American College of Surgeons (FACS) (2017), a shift of outpatient procedures from hospitals to ambulatory care services would save US$ 25 Bn to Medicare over 10 years.
http://www.credenceresearch.com/report/north-america-cystoscopes-market
Redigert 19.01.2021 kl 19:24
Du må logge inn for å svare
Ja og her ser vi vad eksperter spår fremover, men vi har våre egne her på forumet og de er vel ikke ense.
Men det viser seg med tiden, dette blir bra.
Men det viser seg med tiden, dette blir bra.
sokaratest
26.04.2018 kl 08:09
2814
Her ser det ut som om perspektivene stemmer med våre optimistiske antagelser
Medisinmannen
26.04.2018 kl 08:57
2768
Potensialet er det ingen som betviler. Det er også lett å dokumentere potensialet.
Det de aller fleste av oss er kritisk til er om ledelsen evner å lykkes kommersielt.
Det de aller fleste av oss er kritisk til er om ledelsen evner å lykkes kommersielt.
Det er jo medicare som organiserer de fleste eldre pasienter og spar de penger på BLC. Så skall det vel ikke så
mye til før det blir brukt. De står jo for store deler av sykehusens inntekter og dermed har stor makt vad de skall bruke.
Og de vet godt att det beste for dem og pasienten er blålys, og det kommer garantert att bli mye brukt i fremtiden
om det ikke kommer någet bedre. Og regner de med att spare 25 milliarder dollar på 10 år, så får man anta att
de får fart på blålys og. Trur ikke ledelsen klarer att stoppe det engang om de vil..
mye til før det blir brukt. De står jo for store deler av sykehusens inntekter og dermed har stor makt vad de skall bruke.
Og de vet godt att det beste for dem og pasienten er blålys, og det kommer garantert att bli mye brukt i fremtiden
om det ikke kommer någet bedre. Og regner de med att spare 25 milliarder dollar på 10 år, så får man anta att
de får fart på blålys og. Trur ikke ledelsen klarer att stoppe det engang om de vil..
Medisinmannen
26.04.2018 kl 11:24
2683
Guidelines: Har man blålys tilgjengelig så skal man bruke dette i en stor del av tilfellene.
bravi
26.04.2018 kl 12:41
2621
At det star i guidelines er ingen garanti for at det blir brukt på alle pasientene som trenger det.
Det kan umulig bli brukt så mye som guideline anbefaler når hvert skop brukes bare 1 gang per uke i EU og USA.
Det kan umulig bli brukt så mye som guideline anbefaler når hvert skop brukes bare 1 gang per uke i EU og USA.
Du har sikkert rett Bravi. Det her gjengen aner nok inget om bruk av blålys.
Credence Research is a worldwide firm, containing more than 15 research consultants and almost 100 research and information professionals.
Our customers mirror our worldwide nature. Around 45% are in Europe, 30% in the Americas, 13% in Asia Pacific and 12% in the Middle East and Africa.
Our firm is intended to work as one. We are a solitary global research organization united by a solid arrangement of qualities, concentrated on customer effect.
Credence Research is a worldwide firm, containing more than 15 research consultants and almost 100 research and information professionals.
Our customers mirror our worldwide nature. Around 45% are in Europe, 30% in the Americas, 13% in Asia Pacific and 12% in the Middle East and Africa.
Our firm is intended to work as one. We are a solitary global research organization united by a solid arrangement of qualities, concentrated on customer effect.
BenteBazooka
26.04.2018 kl 15:12
2528
Urologene følger nok retningslinjene såfremt klinikken får dekket ekstra utgiftene BLC medfører.
Frem til 01.01.2018 var det bare pasienter med helseforsikring. Evt kanskje noen få som betalte av egen lomme
Frem til 01.01.2018 var det bare pasienter med helseforsikring. Evt kanskje noen få som betalte av egen lomme
Medisinmannen
26.04.2018 kl 15:43
2510
Det er mulig, men det er en fordel at det anbefales sterkere enn noe annet i guidelines. Enig?
focuss
26.04.2018 kl 15:55
2499
Det er viktig at pasienter blir godt informert om fordelen ved å bruke BLC Cysview. Blir de informert, og sitter igjen med den forståelsen som fase 3 dokumentasjonen gir, så flyr de om nødvendig over hele USA for å bli behandlet på en betryggende måte. Hvor mange % av fastleger henviser nå til sykehus med BLC Cysview? Viktig for PHO og markedsføre mot denne gruppen også. Teamet i USA får nok å gjøre fremover og håper de har hatt det en stund allerede.
Eg har egentlig nok aksjer, men småpostene på en stk skal vi klare å ta imot. Lurer på og starte og kjøpe en og en på reint faenskap.